This external quality assessment (EQA) to assess the ability of national reference laboratories from EU/EEA Member States to correctly perform laboratory serodiagnostic tests for pertussis was a collaborative study organised from February to April 2016.
In order to explore whether the current capacity for EU/EEA-wide molecular characterisation for surveillance of HBV and HCV is sufficient to be feasible and what gaps need to be addressed, a survey of EU/EEA Member States was conducted to assess their laboratory capacity and needs in relation to the molecular characterisation of hepatitis B and C.
This is the second report of the 2017–18 influenza season. As of week 1/2018, nearly 37 000 influenza detections across the WHO European Region have been reported.